Article 1 to 10 out of 10 concerning ExonHit Therapeutics SA
bioMérieux and ExonHit Therapeutics initiate their third diagnostic program(01/09/2007) bioMérieux and ExonHit Therapeutics announced the initiation of their third programme for the screening of cancer from blood. One of the goals is to assist physicians in deciding whether to proceed with surgery for prostate cancer. The collaboration ...
Exonhit presents new opportunities in blood diagnostics in neurodegenerative diseases(12/06/2005) Identification of new markers for BSE in collaboration with Roche Applied Science ExonHit Therapeutics announced that the company has identified new blood markers in collaboration with Roche Applied Science for the detection of bovine spongiform encephalopathy (BSE) in living animals. The development of a blood-based BSE test ...
Development of blood diagnostics for the early detection of cancers(10/14/2005) bioMérieux and ExonHit Therapeutics Extend their Strategic Collaboration bioMérieux and ExonHit announced that they signed an agreement to extend their collaboration for six years for the discovery and development of new blood diagnostics in the area of early cancer detection.These diagnostic tests are completely novel ...
ExonHit Therapeutics Expands Strategic Alliance with Allergan(05/20/2005) ExonHit Therapeutics announced that its strategic alliance with Allergan, Inc. has been extended by mutual agreement based on the positive results achieved to date. This will enable both companies to continue their successful collaboration for the ...
Exonhit Therapeutics Granted News Patent in Microarray Market(04/26/2005) ExonHit Therapeutics announced the grant of a major patent (No US #6,881,571) on microarray products allowing the specific detection of mRNAs produced by alternative splicing, covering microarrays optimised for the discovery of alternative RNA ...
French ExonHit Therapeutics Achieves First Research Milestone in its Collaboration with Allergan(12/14/2004) Compound Synthesized at ExonHit Demonstrates Promising Preclinical Profile ExonHit Therapeutics announced that it has reached a first research milestone in its collaboration with Allergan. A new orally active small molecule was synthesized by ExonHit's chemists to modulate a pathway identified by ExonHit's alternative ...
Agilent Technologies and French ExonHit Therapeutics to Collaborate(12/02/2004) Companies Working to Optimize Microarray Technology for Splice Variant Analysis Agilent Technologies Inc. and ExonHit Therapeutics announced a research collaboration to combine Agilent's microarray platform and ExonHit's alternative RNA splicing technologies and expertise. This collaboration explores the development of a ...
ExonHit Therapeutics Accelerates its Clinical Development Programme in Alzheimer's Disease(11/23/2004) EHT 0202 shows potential for Alzheimer's disease and other neuro-degenerative and cognitive ExonHit Therapeutics announced that it plans to start a Phase IIa proof-of-concept study in Alzheimer's disease with EHT 0202, its most advanced compound in development in the early part of 2005. The company has already demonstrated that EHT 0202 ...
Top
